BRCA time's up - GTG
Thursday, 23 October, 2008
Genetic Technologies (ASX: GTG) will enforce its patent rights on diagnostic testing for the BRCA1 and BRCA2 breast cancer genes from November 6, The Age newspaper reports.
GTG holds an exclusive licence to US biotech Myriad Genetics’ diagnostic tests for the gene mutations, which confer a vastly increased risk of developing breast cancer on carriers.
Approximately 10 laboratories in Australia currently provide the tests. All will now be done at GTG’s new lab in Melbourne.
The Australian Consumer and Competition Commission is currently investigating the matter.
A new report on the Myriad story by Professor Richard Gold of Canada’s McGill University is available here.
GTG yesterday announced that Grahame Leonard had withdrawn his consent to act as a director of the company.
Leonard was put forward for election to the board by GTG’s former CEO and major shareholder, Dr Mervyn Jacobson.
Jacobson is attempting to remove four members of the board and its current CEO, Michael Ohanessian.
The company will decide the issue at its AGM on November 19.
Lead exposure linked to memory problems, even decades later
Historic lead levels from the era of leaded petrol may be contributing to cognitive issues 50...
New vulnerability found in the aging brain
An international research team has discovered that in the aging brain, certain proteins are lost...
Genetic weak spot found in hard-to-treat cancers
Research shows that blocking minor splicing can markedly slow tumour growth in liver, lung and...
